Valuation: Starpharma Holdings Limited

Market Cap 381M 271M 236M 223M 203M 380M 26.02B 2.67B 1.03B 13.23B 1.02B 996M 42.57B P/E 2027 *
400x
P/E 2028 * 27.6x
Enterprise Value 335M 238M 208M 196M 178M 334M 22.87B 2.35B 907M 11.63B 895M 875M 37.41B EV / Sales 2027 *
14x
EV / Sales 2028 * 8.62x
Free-Float
70.11%
Yield 2027 *
-
Yield 2028 * -
1 day+3.90%
1 week+1.91%
Current month+11.11%
1 month+14.29%
3 months+14.29%
6 months+72.04%
Current year+122.22%
1 week 0.72
Extreme 0.715
0.8
1 month 0.7
Extreme 0.695
0.83
Current year 0.33
Extreme 0.33
0.83
1 year 0.12
Extreme 0.12
0.83
3 years 0.08
Extreme 0.082
0.83
5 years 0.08
Extreme 0.082
1.5
10 years 0.08
Extreme 0.082
2.52
Manager TitleAgeSince
Chief Executive Officer - 08/01/2024
Director of Finance/CFO - 03/04/2023
Human Resources Officer - 01/06/2022
Director TitleAgeSince
Chairman 81 13/06/2014
Director/Board Member 55 01/03/2020
Director/Board Member - 01/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
8/11/26 A Buy

Chairman

350,001 0.0734%
8/11/26 A Buy

Director

22,741 0.0048%
8/11/26 A Buy

Chief Executive Officer

16,667 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
+3.90%+1.91%+540.00%+471.43% 261M
-0.69%+2.44%+49.81%+100.06% 1,027B
-0.01%+1.63%+54.98%+66.13% 651B
+0.10%+2.69%+18.94%+71.51% 467B
-1.22%+3.66%+36.44%+38.32% 350B
-0.79%+2.73%+19.03%+25.08% 268B
+0.58%+6.76%+11.13%+16.52% 257B
+0.82%+1.45%+38.78%+45.47% 205B
+0.79%+1.84%-28.27%-56.71% 190B
-0.05%+4.77%+32.52%+99.11% 187B
Average +0.31%+2.05%+77.34%+87.69% 360.24B
Weighted average by Cap. -0.25%+2.62%+34.79%+61.30%

Financials

2027 *2028 *
Net sales 24M 17.06M 14.88M 14.05M 12.76M 23.9M 1.64B 168M 64.93M 832M 64.09M 62.67M 2.68B 37.5M 26.66M 23.25M 21.95M 19.93M 37.34M 2.56B 263M 101M 1.3B 100M 97.92M 4.18B
Net income 1.2M 853K 744K 702K 638K 1.2M 81.86M 8.41M 3.25M 41.62M 3.2M 3.13M 134M 14.7M 10.45M 9.11M 8.6M 7.81M 14.64M 1B 103M 39.77M 510M 39.26M 38.38M 1.64B
Net Debt -46.2M -32.84M -28.64M -27.04M -24.56M -46.01M -3.15B -324M -125M -1.6B -123M -121M -5.16B -58.4M -41.52M -36.2M -34.18M -31.04M -58.16M -3.98B -409M -158M -2.03B -156M -152M -6.52B
Logo Starpharma Holdings Limited
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.
Employees
50
Date Price Change Volume
18/09/26 A$0.8000 +3.90% 3,537,042
17/09/26 A$0.7700 +1.32% 3,527,198
16/09/26 A$0.7600 +2.01% 1,798,686
15/09/26 A$0.7450 +0.68% 1,697,837
14/09/26 A$0.7400 +4.96% 1,617,584
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8000AUD
Average target price
1.250AUD
Spread / Average Target
+56.25%

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!